ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

OPGN OpGen Inc

0.449
-0.086 (-16.07%)
30 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
OpGen Inc OPGN NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.086 -16.07% 0.449 18:44:30
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.50 0.4026 0.50 0.403 0.535
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
29/4/202415:05GLOBEOpGen Provides Update on Business Operations and Strategic..
23/4/202415:15GLOBEOpGen Receives Nasdaq Notice Regarding Delayed Form 10-K
26/3/202415:20APSShares Rip In Reaction To Activist Investor Becoming CEO
25/3/202415:05GLOBEOpGen Announces Acquisition of Preferred Stock by David..
13/2/202415:30EDGAR2Form 8-K - Current report
08/2/202406:30EDGAR2Form 8-K - Current report
09/1/202415:30EDGAR2Form 8-K - Current report
12/12/202315:58EDGAR2Form 8-K - Current report
05/12/202315:37EDGAR2Form 8-K - Current report
23/11/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
14/11/202315:30GLOBEOpGen Reports Third Quarter 2023 Financial Results and..
13/11/202315:59EDGAR2Form S-3 - Registration statement under Securities Act of..
07/11/202315:30EDGAR2Form 8-K - Current report
26/10/202315:30EDGAR2Form 8-K - Current report
16/10/202315:30EDGAR2Form 8-K - Current report
13/10/202316:18EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/10/202316:17EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
13/10/202316:15EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/10/202316:14EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/10/202316:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
12/10/202311:32GLOBEOpGen Enters Into Warrant Inducement Transaction for up to..
11/10/202315:40EDGAR2Form 8-K - Current report
11/10/202315:30EDGAR2Form 8-K - Current report
28/9/202315:24EDGAR2Form RW - Registration Withdrawal Request
08/9/202315:30EDGAR2Form 8-K - Current report
07/9/202315:30EDGAR2Form 8-K - Current report
14/8/202307:45EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202315:31EDGAR2Form 8-K - Current report
10/8/202315:15GLOBEOpGen Reports Second Quarter 2023 Financial Results and..
07/8/202306:30GLOBEOpGen’s Subsidiary Ares Genetics Releases New Features to..
03/8/202307:00GLOBEOpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration..
03/8/202306:30GLOBEOpGen to Provide Business Update and Financial Results for..
01/8/202308:40EDGAR2Form DEF 14A - Other definitive proxy statements
21/7/202315:55EDGAR2Form PRE 14A - Other preliminary proxy statements
19/7/202306:30GLOBEOpGen’s Subsidiary Curetis Meets Milestones of Extended and..
14/7/202315:30EDGAR2Form S-1 - General form for registration of securities under..
05/7/202315:30EDGAR2Form 8-K - Current report
30/6/202315:30EDGAR2Form 8-K - Current report
26/6/202306:30GLOBEOpGen Subsidiary Ares Genetics Successfully Maintains Key..
22/6/202306:30GLOBEOpGen’s Subsidiary Curetis Receives Batch of Ten New..
20/6/202306:30GLOBEOpGen Presents Unyvero Urinary Tract Infection Panel Trial..
15/5/202315:15GLOBEOpGen Reports First Quarter 2023 Financial Results and..
08/5/202306:30GLOBEOpGen to Provide Business Update and Financial Results for..
04/5/202315:30GLOBEOpGen Announces Closing of $3.5 Million Public Offering
01/5/202320:00GLOBEOpGen Announces Pricing of $3.5 Million Public Offering

Su Consulta Reciente

Delayed Upgrade Clock